entertainment -WSS

entertainment

author：leisure time 2025-09-05 09:16:37 - browse：5375

Sanofi, the Paris-based drug giant, announced Friday that it would spin out its $5 billion consumer health division, which is exploring over-the-counter moves for the erectile dysfunction drug Cialis and the flu treatment Tamiflu.

Investors reacted swiftly, bidding Sanofi’s American depository receipts on the New York Stock Exchange down nearly 18% to less than $44 in morning trading. Jared Holz, an analyst at Mizuho, warned investors that the drop “would be the largest negative single-day stock move across Global Pharma in more than ten years.”

It would be tempting to take the stock move as evidence that investors have finally tired of watching drug companies treat consumer product divisions like baseball trading cards, buying them at a high price only to sell them again a decade later. But the move probably has little to do with the current passion for pharma spinouts or with Sanofi following in the footsteps of GSK, Novartis, and Pfizer in shedding a division. Or even, for that matter, Sanofi, which shed its pharmaceutical ingredients business, EuroAPI, which is now trading at a third of its initial public offering price.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： How to save PrEP access — and even expand it
Next article： Use wet bulb globe temperature, not heat index, to protect workers

WSS

First recipient of genetically engineered pig kidney has died

Disclosing genetic information: not as worrisome as once feared

With FDA staff opposed to Sarepta therapy, top official intervened

Study: Lilly Alzheimer's therapy slowed patients' cognitive decline

Alcohol isn't healthy after all. Will new dietary guidelines reflect that?

The battle over the Brookhaven Landfill on Long Island

entertainment

entertainment

leisure time

In Memoriam: Notable people who died in 2023

It shouldn't be easy to buy synthetic DNA to recreate a deadly virus

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

Telehealth startups turn to complex chronic diseases

New air purifier tech could be key to improving indoor air quality

With FDA staff opposed to Sarepta therapy, top official intervened

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

Alcohol isn't healthy after all. Will new dietary guidelines reflect that?

Alkermes shareholders re

The strategy behind pharma's lawsuits over drug pricing reform

explore

Cloning humans is technically possible. It's curious no one has tried

Telehealth startups turn to complex chronic diseases

Paxlovid study fails to answer questions over benefit for broader groups

Bird flu outbreak in cows is latest avian flu curveball

Do masks work? RCTs can't tell us

Paxlovid study fails to answer questions over benefit for broader groups

focus

focus

hotspot

focus